Inflammatory bowel diseases (IBD) are costly, chronic illnesses. Key cost-drivers of IBD healthcare expenditures include pharmaceuticals and unplanned care, but evolving treatment approaches have shifted these factors. We aimed to assess changes in cost of care, determine shifts in IBD cost-drivers, and examine differences by socioeconomic and insurance status over time.